• Open Access

SIRT1 and SIRT2: emerging targets in neurodegeneration

Authors

  • Gizem Donmez,

    Corresponding author
    1. Department of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, USA
    • Tel: +1 617 636 3985; Fax: +1 617 636 2413
    Search for more papers by this author
  • Tiago F. Outeiro

    Corresponding author
    1. Department of Neurodegeneration and Restorative Research, Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center, Göttingen, Göttingen, Germany
    • Tel: +49 5513913545; Fax: +49 5513922693
    Search for more papers by this author

Abstract

Sirtuins are NAD-dependent protein deacetylases known to have protective effects against age-related diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases. In mammals, there are seven sirtuins (SIRT1-7), which display diversity in subcellular localization and function. While SIRT1 has been extensively investigated due to its initial connection with lifespan extension and involvement in calorie restriction, important biological and therapeutic roles of other sirtuins have only recently been recognized. Here, we review the potential roles and effects of SIRT1 and SIRT2 in neurodegenerative diseases. We discuss different functions and targets of SIRT1 and SIRT2 in a variety of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's Disease (HD). We also cover the role of SIRT1 in neuronal differentiation due to the possible implications in neurodegenerative conditions, and conclude with an outlook on the potential therapeutic value of SIRT1 and SIRT2 in these disorders.

Ancillary